Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1608 participants.

Also called NCT02316886

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,608 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02316886
Other papers using this trial's data
  • Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial Lancet (London, England), 2024-05-04 DOI, PubMed 38604213 PubMed links an erratum for this paper. Erratum: PMID 39550171

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Japan, New Zealand, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02316886. Randomized; no masking; primary purpose treatment. Start 2015-10-05 (actual); primary completion 2023-10-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque
Acronym
PREVENT
Condition
Plaque, Atherosclerotic
Intervention (Device)
Coronary intervention
Intervention (Drug)
Optimal Medical treatment
Lead sponsor
Seung-Jung Park (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)

Record details

Record id
cardio:ct-nct02316886
Content hash
50ee2d81691f12973e2105c1630219db0c8b9eb47b38174d9170160b5f679298